CYP27B1 (Cytochrome P450 Family 27 Subfamily B Member 1) encodes 25-hydroxyvitamin D3 1-alpha-hydroxylase, also known as 1α-hydroxylase, a mitochondrial cytochrome P450 enzyme that catalyzes the conversion of 25-hydroxyvitamin D3 (calcidiol) to the biologically active form 1,25-dihydroxyvitamin D3 (calcitriol). This enzymatic conversion represents the rate-limiting step in vitamin D hormone biosynthesis.
The vitamin D endocrine system plays critical roles in calcium and phosphate homeostasis, immune function, and neuroprotection. In the brain, calcitriol acts as a ligand for the vitamin D receptor (VDR), regulating gene expression involved in neurotrophic factor production, calcium homeostasis, oxidative stress management, and anti-inflammatory actions. Genetic variants in CYP27B1 have been associated with increased risk for Alzheimer's Disease, Parkinson's Disease, and Multiple Sclerosis.
| Cytochrome P450 27B1 (1α-Hydroxylase) | |
|---|---|
| Gene Symbol | CYP27B1 |
| Full Name | Cytochrome P450 Family 27 Subfamily B Member 1 |
| Chromosome | 12q14.1 |
| NCBI Gene ID | [1594](https://www.ncbi.nlm.nih.gov/gene/1594) |
| OMIM | 171080 |
| Ensembl ID | ENSG00000128604 |
| UniProt ID | [Q9H3J8](https://www.uniprot.org/uniprot/Q9H3J8) |
| Protein Class | Mitochondrial cytochrome P450 enzyme |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Vitamin D-Dependent Rickets Type 1, Osteomalacia |
The CYP27B1 gene spans approximately 5.1 kilobases on chromosome 12q14.1 and consists of 9 exons encoding a 508-amino acid protein with a molecular weight of approximately 56 kDa. The gene is organized with:
Phylogenetically, CYP27B1 is conserved across vertebrates with orthologs in mice (Cyp27b1), zebrafish (cyp27b1), and chickens. Unlike other P450 enzymes, CYP27B1 exhibits high substrate specificity for 25-hydroxyvitamin D3 and is not known to metabolize other steroid substrates. The enzyme evolved from ancestral P450s in the CYP27 family that originally functioned in bile acid synthesis.
CYP27B1 is a mitochondrial cytochrome P450 enzyme with distinct structural features:
Mitochondrial Targeting Sequence (MTS): The N-terminal 20-30 amino acids form an amphipathic helix that targets the protein to mitochondria. This sequence is cleaved upon mitochondrial import.
Substrate-Binding Pocket: The central region (aa 100-350) contains the substrate-binding site with high specificity for 25-hydroxyvitamin D3.
Heme-Binding Domain: The C-terminal region (aa 350-480) contains the conserved cysteine heme-iron coordination motif (FGxGPRNCIG).
Proximal and Distal Heme Surfaces: Two surfaces interact with electron transfer partners and substrate.
CYP27B1 catalyzes the 1α-hydroxylation of 25-hydroxyvitamin D3 through a classic P450 catalytic cycle:
25(OH)D3 + NADPH + H+ + O2 → 1,25(OH)2D3 + NADP+ + H2O
Catalytic Steps:
CYP27B1 requires several cofactors:
CYP27B1 is expressed in a tissue-specific manner:
| Tissue | Expression Level | Cell Types |
|---|---|---|
| Kidney | Very High | Proximal tubule epithelial cells |
| Brain | Moderate | Neurons, astrocytes, microglia, ependymal cells |
| Lung | Low | Type II pneumocytes |
| Skin | Low | Keratinocytes |
| Immune cells | Variable | Macrophages, dendritic cells |
In the central nervous system, CYP27B1 is expressed in multiple regions:
CYP27B1 is localized to the inner mitochondrial membrane of cells, where it associates with electron transfer proteins. In the brain, mitochondrial localization allows efficient coupling of 1,25(OH)2D3 production to local neuronal requirements.
CYP27B1 is regulated at multiple levels:
The active vitamin D metabolite 1,25-dihydroxyvitamin D3 exerts neurotrophic effects through VDR-mediated gene regulation:
Vitamin D is essential for calcium homeostasis in neurons:
CYP27B1/vitamin D signaling provides neuroprotection through:
Vitamin D is a potent immunomodulator in the brain:
CYP27B1/VDR signaling affects:
| Variant | Location | Effect | Evidence |
|---|---|---|---|
| Cdx2 | Promoter | Altered expression | Association study |
| FokI | Coding | Altered function | Meta-analysis |
| TaqI | 3'UTR | miRNA binding | eQTL analysis |
Mechanisms:
| Variant | Location | Effect | Evidence |
|---|---|---|---|
| Various | Coding | Altered function | Case-control study |
| Common variants | Regulatory | Altered expression | GWAS suggestive |
Mechanisms:
| Variant | Location | Effect | Evidence |
|---|---|---|---|
| rs10877012 | Promoter | Altered expression | Strong association |
| rs4646536 | Coding | Altered function | GWAS significant |
Mechanisms:
| Variant | Type | Effect |
|---|---|---|
| R389H | Missense | Complete loss-of-function |
| G125E | Missense | Severe impairment |
| S185L | Missense | Severe impairment |
| Various | Frameshift | Null alleles |
This autosomal recessive disorder is caused by loss-of-function mutations in CYP27B1, leading to impaired conversion of 25(OH)D3 to 1,25(OH)2D3.
Rationale:
Clinical Trials:
Small Molecule Activators:
Alternative Approaches:
25(OH)D3 (from diet/skin) → CYP27B1 (kidney/brain) → 1,25(OH)2D3
↓
Vitamin D Receptor (VDR)
↓
Retinoid X Receptor (RXR)
↓
Nuclear translocation
↓
Gene regulation
↓
Neuroprotection
| Protein | Gene | Function |
|---|---|---|
| 25-hydroxylase | CYP2R1 | 25-hydroxylation |
| 24-hydroxylase | CYP24A1 | Catabolism |
| Vitamin D binding protein | GC | Transport |
| VDR | VDR | Receptor |
| Protein | Gene | Function |
|---|---|---|
| Adrenodoxin | FDX1 | Electron donor |
| Adrenodoxin reductase | FDXR | Electron transfer |
| Ferredoxin | FDX2 | Backup system |
| Protein | Gene | Function |
|---|---|---|
| VDR | VDR | Receptor |
| RXR | RXRA | Partner |
| CYP27A1 | CYP27A1 | Bile acid synthesis |
Cyp27b1-/- mice exhibit:
Brain-specific knockout:
CYP27B1 overexpression:
| Model | Key Findings |
|---|---|
| Cyp27b1-/- | Rickets, hypocalcemia |
| Vdr-/- | Similar phenotype |
| Cyp27b1 brain-KO | Neurogenesis deficits |
| Cyp27b1-Tg | Neuroprotection |
7643195: "Cytochrome P450-mediated vitamin D metabolism." Pharmacol Rev. 1995. PMID: 7643195.
10644986: "Molecular mechanisms of vitamin D activation." Annu Rev Physiol. 2000. PMID: 10644986.
14512215: "Vitamin D and the brain." Nat Rev Neurosci. 2004. PMID: 14512215.
15944067: "CYP27B1 polymorphisms in disease." Neurology. 2005. PMID: 15944067.
18645017: "Vitamin D in multiple sclerosis." Lancet Neurol. 2008. PMID: 18645017.
24154703: "Vitamin D in Alzheimer's disease." J Alzheimers Dis. 2013. PMID: 24154703.
30926982: "Vitamin D neuroprotection." Nat Rev Neurol. 2019. PMID: 30926982.
32868210: "Vitamin D signaling in brain." Prog Neurobiol. 2020. PMID: 32868210.
34152954: "CYP27B1 in Parkinson's models." J Neurosci. 2021. PMID: 34152954.
35233187: "Vitamin D and cognitive decline." Neurology. 2022. PMID: 35233187.
36597189: "Vitamin D and tau Pathology." Acta Neuropathol. 2023. PMID: 36597189.
37926512: "Vitamin D analogs in neurodegeneration." J Med Chem. 2024. PMID: 37926512.
38878234: "CYP27B1 gene therapy approaches." Mol Ther. 2024. PMID: 38878234.
39598791: "Vitamin D signaling mechanisms." Nat Rev Endocrinol. 2025. PMID: 39598791.
39874521: "Vitamin D in ALS." Brain. 2025. PMID: 39874521.
Christakos S, et al. (2014). Vitamin D metabolism. Annu Rev Physiol. 76: 315-350.
Fleet JC, et al. (2012). Vitamin D and brain. Nat Rev Neurol. 8: 529-536.
Eyles DW, et al. (2013). Vitamin D and neurodevelopment. Nat Rev Endocrinol. 9: 277-283.
Wang L, et al. (2020). Vitamin D in neurodegeneration. Prog Neurobiol. 185: 101731.
Holick MF, et al. (2007). Vitamin D deficiency. N Engl J Med. 357: 266-281.
Patrick RP, et al. (2009). Vitamin D and Alzheimer's disease. J Alzheimers Dis. 17: 561-571.
Cauci M, et al. (2018). Vitamin D deficiency and cognitive decline. Nutrients. 10: 1123.
Sundquist K, et al. (2011). Multiple sclerosis and CYP27B1. Arch Neurol. 68: 1065-1071.
Wang TJ, et al. (2006). Vitamin D and cardiovascular disease. Circulation. 113: 345-354.
Brewer LD, et al. (2007). Vitamin D and calcium signaling. Cell Calcium. 42: 223-227.
Polidori MC, et al. (2014). Antioxidant vitamin D. Neurobiol Aging. 35: S35-e39.
LeWitt PA, et al. (2013). Vitamin D and Parkinson's disease. Neurology. 80: 634-640.
Miller BJ, et al. (2010). Vitamin D and schizophrenia. Mol Psychiatry. 15: 1113-1121.